The Association Between Green Tea Intake and Metabolic Syndrome: A Systematic Review and Meta-analysis of Randomized Controlled Trials.

IF 3.6 4区医学 Q2 PHARMACOLOGY & PHARMACY

Clinical therapeutics Pub Date : 2025-10-09 DOI:10.1016/j.clinthera.2025.09.011

Sahar Ghoflchi, Hadiseh Mohammadi, Maryam Teimouri, Masoud Imani, Hossein Hosseini

{"title":"The Association Between Green Tea Intake and Metabolic Syndrome: A Systematic Review and Meta-analysis of Randomized Controlled Trials.","authors":"Sahar Ghoflchi, Hadiseh Mohammadi, Maryam Teimouri, Masoud Imani, Hossein Hosseini","doi":"10.1016/j.clinthera.2025.09.011","DOIUrl":null,"url":null,"abstract":"Introduction: This review is the first to assess the effects of green tea on blood pressure, lipid profile, and glucose in people with metabolic syndrome, highlighting its potential anti-inflammatory and metabolic benefits.Methods: We used Standardized Mean Differences (SMD) and Cohen's d for group comparisons, while heterogeneity and publication bias were assessed using the I² statistic, Cochrane Q test, Begg's funnel plot, and Egger's test.Results: Our results showed that green tea consumption did not significantly affect FBS (SMD: -0.03; 95%; P = 0.95), HbA1C (SMD: 4.87; 95%; P = 0.63), systolic blood pressure (SMD: -0.42; 95%; P = 0.36), diastolic blood pressure (SMD: -0.24; 95%; P = 0.53), total cholesterol (SMD: -0.38; 95%; P = 0.19), TG (SMD: -0.17; 95%; P = 0.34), HDL-C (SMD: -0.07; 95%; P = 0.75), or LDL-C (SMD: -0.45; 95%; P = 0.25). Subgroup analyses showed that short-term green tea intake (<8 weeks) significantly reduced FBS (SMD: -1.62), total cholesterol (SMD: -1.09), TG (SMD: -0.74), and LDL-C (SMD: -0.83). Doses below 3000 mg/day were also linked to lower total cholesterol (SMD: -0.69) and LDL-C (SMD: -0.83). Among women, green tea improved total cholesterol (SMD: -0.79), HDL-C (SMD: 0.50), LDL-C (SMD: -1.25), and systolic blood pressure (SMD: -1.74), despite overall high heterogeneity and publication bias.Conclusion: Although our results found no significant difference in the measurement factor in patients with MetS. subgroup analyses suggested potential benefits in women, those consuming lower doses (<3000 mg/day), and those with shorter intervention durations (<8 weeks).","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clinthera.2025.09.011","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: This review is the first to assess the effects of green tea on blood pressure, lipid profile, and glucose in people with metabolic syndrome, highlighting its potential anti-inflammatory and metabolic benefits.

Methods: We used Standardized Mean Differences (SMD) and Cohen's d for group comparisons, while heterogeneity and publication bias were assessed using the I² statistic, Cochrane Q test, Begg's funnel plot, and Egger's test.

Results: Our results showed that green tea consumption did not significantly affect FBS (SMD: -0.03; 95%; P = 0.95), HbA1C (SMD: 4.87; 95%; P = 0.63), systolic blood pressure (SMD: -0.42; 95%; P = 0.36), diastolic blood pressure (SMD: -0.24; 95%; P = 0.53), total cholesterol (SMD: -0.38; 95%; P = 0.19), TG (SMD: -0.17; 95%; P = 0.34), HDL-C (SMD: -0.07; 95%; P = 0.75), or LDL-C (SMD: -0.45; 95%; P = 0.25). Subgroup analyses showed that short-term green tea intake (<8 weeks) significantly reduced FBS (SMD: -1.62), total cholesterol (SMD: -1.09), TG (SMD: -0.74), and LDL-C (SMD: -0.83). Doses below 3000 mg/day were also linked to lower total cholesterol (SMD: -0.69) and LDL-C (SMD: -0.83). Among women, green tea improved total cholesterol (SMD: -0.79), HDL-C (SMD: 0.50), LDL-C (SMD: -1.25), and systolic blood pressure (SMD: -1.74), despite overall high heterogeneity and publication bias.

Conclusion: Although our results found no significant difference in the measurement factor in patients with MetS. subgroup analyses suggested potential benefits in women, those consuming lower doses (<3000 mg/day), and those with shorter intervention durations (<8 weeks).

查看原文本刊更多论文

绿茶摄入与代谢综合征之间的关系：随机对照试验的系统回顾和荟萃分析。

本综述首次评估了绿茶对代谢综合征患者血压、血脂和血糖的影响，强调了其潜在的抗炎和代谢益处。方法：采用标准化平均差异（SMD）和Cohen’s d进行组间比较，采用I²统计量、Cochrane Q检验、Begg’s漏斗图和Egger’s检验评估异质性和发表偏倚。结果：我们的研究结果显示，绿茶摄入对FBS （SMD: -0.03; 95%; P = 0.95）、HbA1C （SMD: 4.87; 95%; P = 0.63）、收缩压（SMD: -0.42; 95%; P = 0.36）、舒张压（SMD: -0.24; 95%; P = 0.53）、总胆固醇（SMD: -0.38; 95%; P = 0.19）、TG （SMD: -0.17; 95%; P = 0.34）、HDL-C （SMD: -0.07; 95%; P = 0.75）或LDL-C （SMD: -0.45; 95%; P = 0.25）没有显著影响。亚组分析显示，短期绿茶摄入量(结论：尽管我们的研究结果在met患者的测量因子中没有发现显著差异。亚组分析显示，服用较低剂量的女性(

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical therapeutics 医学-药学

CiteScore

6.00

自引率

3.10%

发文量

154

审稿时长

9 weeks

期刊介绍： Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.